Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MAX-40279 |
Synonyms | |
Therapy Description |
MAX-40279 inhibits FGFRs and FLT3, including known FLT3 resistance mutations such as D835Y, potentially leading to inhibition of tumor growth (Blood (2018) 132 (Supplement 1): 3997). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MAX-40279 | MAX 40279|MAX40279|MAX-40279-01|Max 4 | FGFR Inhibitor (Pan) 26 FLT3 Inhibitor 69 | MAX-40279 inhibits FGFRs and FLT3, including known FLT3 resistance mutations such as D835Y, potentially leading to inhibition of tumor growth (Blood (2018) 132 (Supplement 1): 3997). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03412292 | Phase I | MAX-40279 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | Unknown status | AUS | 0 |